英夫利西单抗、依那西普、阿达木单抗是中国目前上市的治疗强直性脊柱炎(AS)的生物制剂,均为肿瘤坏死因子(TNF-α)抑制剂,具有较高临床效益和治疗成本。本研究就AS的疾病负担及TNF-α抑制剂的药物经济学评价研究进行系统文献综述,为国内药物经济学研究提供参考。 Infliximab, Etanercept and Adalimumab are currently listed in China for the treatment of ankylosing spondylitis (AS) biological agents, are tumor necrosis factor (TNF-α) inhibitors, with high clinical benefit and Treatment costs. This study summarizes the systematic literature review on the disease burden of AS and the pharmacoeconomic evaluation of TNF-α inhibitors, and provides a reference for the domestic study of pharmacoeconomics.